Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

UBC formulation of leishmaniasis drug shown to be stable, effective in tropical temperatures

08.12.2010
A new formulation of Amphotericin B (AmB) developed by University of British Columbia researchers has been shown to be stable in tropical climates and effective in treating Visceral Leishmaniasis (VL) in mouse models.

VL is a blood-born parasitic disease that afflicts 12 million people worldwide, mainly in developing countries and tropical regions. According to the World Health Organization (WHO), 1.5 million new cases of the disease are reported every year, and 60,000 people die from it.

AmB, a 50-year-old anti-fungal drug, is the standard treatment for VL, but its current formulation requires intravenous administration and constant refrigeration, making it costly and challenging to deliver in tropical regions, where VL takes the heaviest toll.

A lipid-based formulation, co-developed by UBC Pharmaceutical Sciences Professor Kishor Wasan and Adjunct Professor Ellen Wasan, allows the drug to be taken orally. It was licensed to Vancouver-based iCo Therapeutics in 2008. As part of the licensing agreement, and in accordance with UBC's Global Access principles, iCo Therapeutics agrees to provide the drug at subsidized costs to developing countries for the treatment of VL.

A new study published today in the online journal PLoS Neglected Tropical Diseases shows that the formulation, called iCo-010, is stable in WHO Climate Zones 3 and 4 (30-43 degrees Celsius) and is efficacious in treating mice with VL.

"In most places where VL is a problem, there is little infrastructure for refrigeration of drug products," says Kishor Wasan, Distinguished University Scholar and co-author of the study. "Now we've shown for the first time this lipid-based formulation can stand up to the harsh conditions of the tropical climate and is effective in animal models when taken orally."

"The development of this thermally stable and efficacious oral formulation brings us one step closer to helping people in remote areas of India, Bangladesh, Nepal and Sudan, where VL is a serious problem," says Ellen Wasan, lead author of the PLoS-NTD paper. Ellen Wasan is an adjunct professor at UBC's Faculty of Pharmaceutical Sciences and a faculty member at the British Columbia Institute of Technology.

The AmB oral formulation is a founding project of the Neglected Global Diseases Initiative (NGDI) at UBC and is funded by the Consortium for Parasitic Drug Development, a grantee of the Bill and Melinda Gates Foundation. Since its launch in 2009, NGDI-associated researchers have received more than $9 million in funding for projects aimed at improving health outcomes for the world's poorest people.

The Neglected Global Diseases Initiative at UBC (NGDI-UBC) aims to bring together the technical expertise and perspectives of a variety of disciplines at UBC – including bench science, pharmaceutical and health research, business, social policy, and law – to develop interventions for neglected global diseases and ensure their delivery to those in need. For more information, visit www.ngdi.ubc.ca.

Brian Lin | EurekAlert!
Further information:
http://www.ubc.ca
http://www.ngdi.ubc.ca

More articles from Studies and Analyses:

nachricht Multi-year study finds 'hotspots' of ammonia over world's major agricultural areas
17.03.2017 | University of Maryland

nachricht Diabetes Drug May Improve Bone Fat-induced Defects of Fracture Healing
17.03.2017 | Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

When Air is in Short Supply - Shedding light on plant stress reactions when oxygen runs short

23.03.2017 | Life Sciences

Researchers use light to remotely control curvature of plastics

23.03.2017 | Power and Electrical Engineering

Sea ice extent sinks to record lows at both poles

23.03.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>